The justified position of rosuvastatin in therapeutic practice


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article focuses on evidence-based knowledge on the use of lipid-lowering drugs. The target blood lipid indicators against the background of the treatment with statins are given, the choice of rosuvastatin for the category of patients who have had an acute cardiac event, myocardial infarction, acute cerebrovascular accident and/or transient ischemic attack is justified. The fundamental positions of international and Russian clinical guidlens on the management of patients after myocardial infarction and cerebral stroke for the prevention of complications, as well as for improving the prognosis, are discussed. The non-lipid pleiotropic effects of rosuvastatin are described. It was noted that the use of rosuvastatin does not create obstacles to its combined administration with antiplatelet agents and anticoagulants, which are necessary for patients of these categories.

Full Text

Restricted Access

About the authors

N. P Lyamina

Moscow Scientific and Practical Center for Medical Rehabilitation, Restorative and Sports Medicine

Email: lyana_n@mail.ru
MD, Professor

A. V Kosareva

Medicine AlphaStrakovanie LLC. Alpha - Health Center

References

  1. ВОЗ. О сердечно-сосудистых заболеваниях (цитировано 10.09.2019). URL: https://www. who./nt/card/ovascu/ar_d/seases/about_cvd/ru
  2. Щербакова Е.М. Россия: предварительные демографические итоги 2018 года (часть I). Демоскоп Weekly. 2019. С. 801-2. URL: http:// demoscope.ru/weekly/2019/0801/barom01.php
  3. Рекомендации ЕОК по ведению пациентов с острым инфарктом миокарда с подъемом сегмента ST 2017. Российский кардиологический журнал. 2018;23(5):103-58. http://dx.doi. org/10.15829/1560-4071-2018-5-103-158
  4. Russia Today. Отбить удар: в Минздраве заявили о снижении смертности от инсульта (цитировано 30.08.2019). Available from: https:// russian.rt.com/russia/article/442868-rossiya-insultsmertnost-snizhenie
  5. Аронов Д.М. Лечение и профилактика атеросклероза. М., 2000. 132 с
  6. Кардиоваскулярная профилактика 2017. Российское кардиологическое общество. Национальное общество профилактической кардиологии. Российское общество профилактики неинфекционных заболеваний. М., 2017. 289 с. https://scardio.ru/content/Guidelines/ Cardiovascular-prof-2017.pdf
  7. Baigent C., Blackwell L., Emberson J., et al., Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. doi: 10.1016/S0140-6736(10)61350-5
  8. Preis S.R., Hwang S.J., Coady S., et al. Trends in allcause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009;119:1728-35. Doi: 10.1161/ CIRCULATIONAHA.108.829176
  9. Cheung B., Lauder I., Lau C., Kumana C. Metaanalysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004;57(5):649 51. doi: 10.1111/j.1365-2125.2003.02060.x
  10. Грацианский Н.А., Ваулин Н.А. Применение липидмодулирующих средств при осложненном течении коронарной болезни сердца. Бюллютень экспериментальной и биологической медицины. 2007;Прил. 2:67-75.
  11. Bellosta S., Ferri N., Bernini F., et al. Non-lipid-related effects of statins. Ann Med. 2000;32(3):164-76.
  12. Catapano A.L., Graham I., De Backer G., et al.; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272.
  13. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации V. пересмотр. М., 2012. 50 с. URL: https://scardio.ru/content/ Guidelines/rek_lipid_2012.pdf.
  14. Ежов М.В., Сергиенко И.В., Аронов Д.М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. VI пересмотр, 2017. Атеросклероз и дислипидемии. 2017;3:5-22
  15. Mach F., Bdigent C., Catapano A.L., et al. 2019 ESC/ EASGuidelinesfor themanagementofdyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Show more. Eur Heart J. 2019;00:178. doi: 10.1093/eurheartj/ ehz455.
  16. Aboyans V., Ricco J.B., Bartelink M.E.L., et al.; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi: 10.1093/eurheartj/ ehx095.
  17. Amarenco P., Bogousslavsky J., Callahan A. 3rd, et al.; Stroke Prevention by Aggressive Reduction in Cholesterol levels (SPARCL) investigators. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl J. Med. 2006;355(6):549-59. doi: 10.1056/NEJMoa061894.
  18. Weng T.C., Yang Y.H., Lin S.J., Tai S.H. A systematic review and meta-analysis on the therapeutic equivalence of statins. J. Clin Pharm Ther. 2010;35(2):139-51. doi: 10.1111/j.1365-2710.2009.01085.x.
  19. Karlson B.W., Palmer M.K., Nicholls S.J., et al. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER metaanalysis. Eur J. Prev Cardiol. 2016;23(7):744-47. doi: 10.1177/2047487315598710.
  20. Karlson B.W., Palmer M.K., Nicholls S.J., et al. Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database. Atherosclerosis. 2017;265:54-9. Doi: 10.1016/j. atherosclerosis.2017.08.014.
  21. Jones PH., Hunninghake D.B., Ferdinand K.C., et al. Statin Therapies for Elevated Lipid Levels Compared Across Doses to osuvastatin Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004;26(9):1388-99. Doi: 10.1016/j. clinthera.2004.09.006.
  22. Затейщиков Д.А. Лечение атеросклероза: насколько важно действие статинов на уровень холестерина? Фарматека. 2003;6:39-43.
  23. Аронов Д.М. Каскад терапевтических эффектов статинов. Кардиология. 2004;10:85-94.
  24. Cay S., Cagirci G., Sen N., et al. Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin. Cardiovasc Drugs Ther. 2010;24(1):41-7. doi: 10.1007/s10557-010-6224-1.
  25. Gomez-Garcfa A., Martinez Torres G., Ortega-Pierres L.E., et al. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. Rev. Esp. Cardiol. 2007;60(12):1242-49. doi: 10.1157/13113929.
  26. Erbs S., Beck E.B., Linke A., et al. High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling - results from a randomized, double-blind, and placebo-controlled study. int J. Cardiol. 2011;146(1):56-63. doi: 10.1016/j.ijcard.2010.02.019.
  27. Parson H.K., Bundy M.A., Dublin C.B., et al. Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes. Diab Metab Syndr Obes. 2010;3:19-26.
  28. Nakahara T., Hyogo H., Kimura Y., et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res. 2012;42(11):1065- 72. doi: 10.1111/j.1872-034X.2012.01034.x.
  29. Neukamm A., Einvik G., lehmann S., et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. J. int Med. 2015;278(1):59-67. doi: 10.1111/joim.12337.
  30. Недогода С.В. Розувастатин: доказательная база и значение для реальной клинической практики. РМЖ. 2015;15:886-90.
  31. Zhang X., Wen J., Zhang Z. Statins use and risk of dementia. A dose-response meta-analysis Medicine. 2018;97:30(e11304). Doi: http://dx.doi. org/10.1097/MD.0000000000011304.
  32. Simpson S.H., Eurich D.T., Majumdar S.R., et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15. doi: 10.1136/bmj.38875.675486.55.
  33. Ковш Е.В., Булгак А.Г., Вельская М.И. и др. Терапевтическая эквивалентность препарата Розулип в сравнении с оригинальным Розувастатином у пациентов с гиперхолестеринемией. РМЖ. 2013;27:1301

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies